Research Achievements

Scientific Articlesby Voluntary Organization JBCRG

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy


Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.


The New England Journal of Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy


Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.


The New England Journal of Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645

Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG


Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.


Breast Cancer 2015 Nov;22(6):586-95.

Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.


Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).


Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.

Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer


Hiroji Iwata, Nobuaki Sato, Norikazu Masuda, Seigo Nakamura, Naohito Yamamoto, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Yasuo Ohashi, and Masakazu Toi


Japanese Journal of Clinical Oncology 41: 867-875, 2011

PhaseII study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival


Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, YamazakiK, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F,Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG)


Breast Cancer Res Treat. 2008 Aug;110(3):531-9. Epub 2007 Sep 19


Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).


Breast Cancer. 2005; 13(1): 38-48.

Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.


Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).


Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.

Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer


Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG).


Biomed Pharmacother.2005 Oct;59 Suppl 2:S323-4.

Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breastcarcinoma


Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y,Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG).


Breast Cancer. 2005;12(2):99-103.

Back to Association JBCRG page